{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:22:24Z","timestamp":1788830544153,"version":"build-2803163510"},"reference-count":42,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>Crohn\u2019s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract that leads to significant deterioration in patients\u2019 quality of life. Biologic therapy, including the use of ustekinumab (UST), is a modern approach to treating the moderate to severe form of CD, especially in patients refractory to traditional treatments. UST, which acts as an interleukin IL-12 and IL-23 antagonist, has shown high efficacy in reducing inflammation, improving quality of life, and promoting mucosal regeneration and fistula healing. However, the use of biologic therapies, such as UST, has challenges related to the timing of treatment and patient response, including the problem of immunogenicity. To determine the clinical efficacy and safety profile of UST in the treatment of CD, a review of the literature published in the PubMed database over the last 5 years was conducted. After excluding articles that did not meet the inclusion criteria, we analyzed 42 clinical studies. The review discusses the available data on the efficacy and safety of UST, as well as its comparison with other biologic therapies, such as infliximab and adalimumab. UST, although not significantly greater to adalimumab, has lower immunogenicity and higher treatment retention. The therapeutic value of UST is also confirmed by biosimilars such as ABP 65 and FYB202, which show comparable efficacy and safety profile. The analysis of predictive biomarkers, such as serum drug levels and baseline eosinophil levels, could be an important element in the future personalization of CD treatment. The review\u2019s findings point to the importance of further research to improve the tailoring of therapies to individual patients and improve long-term treatment outcomes.<\/jats:p>","DOI":"10.3390\/pharmacy13030073","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T07:44:57Z","timestamp":1747813497000},"page":"73","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ustekinumab in the Treatment of Crohn\u2019s Disease\u2014A Narrative Review on Clinical Efficacy and Safety Profile"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8074-0122","authenticated-orcid":false,"given":"Dawid","family":"Piecuch","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Kazimierz Pu\u0142aski University of Radom, 26-601 Radom, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2769-943X","authenticated-orcid":false,"given":"Edyta","family":"Ha\u0144czyk","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Kazimierz Pu\u0142aski University of Radom, 26-601 Radom, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6647-247X","authenticated-orcid":false,"given":"Szymon","family":"Kopcia\u0142","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Kazimierz Pu\u0142aski University of Radom, 26-601 Radom, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3478-9350","authenticated-orcid":false,"given":"Natalia","family":"Pawelec","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Kazimierz Pu\u0142aski University of Radom, 26-601 Radom, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4347-4077","authenticated-orcid":false,"given":"Weronika","family":"Mazur","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Kazimierz Pu\u0142aski University of Radom, 26-601 Radom, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4622-8285","authenticated-orcid":false,"given":"Karolina","family":"Kornatowska","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Kazimierz Pu\u0142aski University of Radom, 26-601 Radom, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"ref_1","unstructured":"Ranasinghe, I.R., Tian, C., and Hsu, R. (2025). Crohn Disease. StatPearls, StatPearls Publishing."},{"key":"ref_2","unstructured":"McDowell, C., Farooq, U., and Haseeb, M. (2025). Inflammatory Bowel Disease. StatPearls, StatPearls Publishing."},{"key":"ref_3","unstructured":"Malik, T.F., and Aurelio, D.M. (2025). Extraintestinal Manifestations of Inflammatory Bowel Disease. StatPearls, StatPearls Publishing."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa2314585","article-title":"Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn\u2019s Disease","volume":"391","author":"Chapman","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1007\/s12325-023-02546-6","article-title":"Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn\u2019s Disease","volume":"40","author":"Dubinsky","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ueg2.12094","article-title":"The impact of ustekinumab on extraintestinal manifestations of Crohn\u2019s disease: A post hoc analysis of the UNITI studies","volume":"9","author":"Narula","year":"2021","journal-title":"UEG J."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Baumgart, D.C., Stallmach, A., Grunert, P., Schubert, S., Howaldt, S., von Arnim, U., Ochsenk\u00fchn, T., Stein, J., L\u00fcgering, A., and Schmidt, D. (2024). Induction and maintenance of mucosal healing in Crohn\u2019s disease with ustekinumab in clinical practice across all care levels in Germany (MUCUS). Sci. Rep., 14.","DOI":"10.1038\/s41598-024-70241-9"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: A multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands","year":"2022","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.cgh.2021.04.006","article-title":"Comparative Efficacy and Rapidity of Action for Infliximab vs. Ustekinumab in Biologic Na\u00efve Crohn\u2019s Disease","volume":"20","author":"Narula","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/j.cgh.2019.11.059","article-title":"Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients with Ulcerative Colitis","volume":"18","author":"Adedokun","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_11","unstructured":"Colquhoun, M., and Kemp, A.K. (2025). Ustekinumab. StatPearls, StatPearls Publishing."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"910","DOI":"10.14309\/ajg.0000000000002621","article-title":"Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study","volume":"119","author":"Afif","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/ecco-jcc\/jjac030","article-title":"Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension","volume":"16","author":"Abreu","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_14","unstructured":"Janssen Inc. (2020). Indication: Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies. Pharmacoeconomic Review Report: Ustekinumab (Stelara\/Stelara I.V.), Canadian Agency for Drugs and Technologies in Health."},{"key":"ref_15","unstructured":"Reuben, A. (2012). Ustekinumab, LiverTox: Clinical and Research Information on Drug-Induced Liver Injury."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/jpn3.12252","article-title":"Ustekinumab in paediatric patients with moderately to severely active Crohn\u2019s disease: UniStar study long-term extension results","volume":"79","author":"Turner","year":"2024","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1093\/ecco-jcc\/jjab089","article-title":"Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn\u2019s Disease: Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 Study","volume":"15","author":"Rosh","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Yao, J.Y., Zhang, M., Wang, W., Peng, X., Zhao, J.Z., Liu, T., Li, Z.W., Sun, H.T., Hu, P., and Zhi, M. (2021). Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn\u2019s disease: A Chinese real-world study. BMC Gastroenterol., 21.","DOI":"10.1186\/s12876-021-01946-8"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s40259-020-00451-w","article-title":"Clinical Trials of IL-12\/IL-23 Inhibitors in Inflammatory Bowel Disease","volume":"34","author":"Almradi","year":"2020","journal-title":"BioDrugs"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","article-title":"Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn\u2019s Disease: The IM-UNITI Trial","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/ecco-jcc\/jjae013","article-title":"Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn\u2019s Disease and 4 Years in Ulcerative Colitis","volume":"18","author":"Ghosh","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/apt.17751","article-title":"Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn\u2019s disease: Results from the long-term extension period of STARDUST","volume":"59","author":"Vermeire","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.cgh.2023.06.014","article-title":"Evolution of Symptoms After Ustekinumab Induction Therapy in Patients with Crohn\u2019s Disease","volume":"22","author":"Colombel","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/ibd\/izac231","article-title":"Predictors of Clinical Remission to Placebo in Clinical Trials of Crohn\u2019s Disease","volume":"29","author":"Wong","year":"2023","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"jjaf006","DOI":"10.1093\/ecco-jcc\/jjaf006","article-title":"Improvement in serum eosinophilia is observed in clinical responders to ustekinumab but not adalimumab in inflammatory bowel disease","volume":"19","author":"Wong","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/ibd\/izaa214","article-title":"Body Mass Index Does Not Impact Clinical Efficacy of Ustekinumab in Crohn\u2019s Disease: A Post Hoc Analysis of the IM-UNITI Trial","volume":"27","author":"Wong","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/ibd\/izaa251","article-title":"Epithelial Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohn\u2019s Disease","volume":"27","author":"Osterman","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_28","first-page":"2099","article-title":"Real-life efficacy and safety of Ustekinumab as second- or third-line therapy in Crohn\u2019s disease: Results from a large Italian cohort study","volume":"25","author":"Tursi","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/ibd\/izaa236","article-title":"Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2\/3 Studies","volume":"27","author":"Sandborn","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/cpdd.1301","article-title":"Pharmacokinetic Similarity of ABP 654, An Ustekinumab Biosimilar Candidate: Results from a Randomized, Double-blind Study in Healthy Subjects","volume":"12","author":"Chow","year":"2023","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cgh.2022.05.055","article-title":"Early Ultrasound Response and Progressive Transmural Remission After Treatment with Ustekinumab in Crohn\u2019s Disease","volume":"21","author":"Kucharzik","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S2468-1253(21)00474-X","article-title":"Treat to target versus standard of care for patients with Crohn\u2019s disease treated with ustekinumab (STARDUST): An open-label, multicentre, randomised phase 3b trial","volume":"7","author":"Danese","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/ueg2.12384","article-title":"Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn\u2019s disease: Results up to Week 104 of the STARDUST trial","volume":"11","author":"Vermeire","year":"2023","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/ibd\/izac168","article-title":"Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Na\u00efve Crohn\u2019s Disease","volume":"29","author":"Wong","year":"2023","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/cpdd.1473","article-title":"New Ustekinumab Biosimilar Candidate FYB202: Pharmacokinetic Equivalence Demonstrated in a Randomized, Double-Blind, Parallel-Group, Single-Dose Trial in Healthy Subjects","volume":"13","author":"Balser","year":"2024","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.14309\/ajg.0000000000002654","article-title":"Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Na\u00efve Crohn\u2019s Disease","volume":"119","author":"Narula","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/ecco-jcc\/jjad047","article-title":"A Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients with Moderately to Severely Active Crohn\u2019s Disease","volume":"17","author":"Allez","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ecco-jcc\/jjz119","article-title":"Ustekinumab for Crohn\u2019s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study","volume":"14","author":"Biemans","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10620-022-07501-z","article-title":"Ustekinumab Is Associated with Real-World Long-Term Effectiveness and Improved Health-Related Quality of Life in Crohn\u2019s Disease","volume":"68","author":"Forss","year":"2023","journal-title":"Dig Dis Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/ecco-jcc\/jjab081","article-title":"Ustekinuma b for Crohn\u2019s Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study","volume":"15","author":"Straatmijer","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/ibd\/izab357","article-title":"Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn\u2019s Disease Patients: The SUSTAIN Study","volume":"28","author":"Chaparro","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/apt.15958","article-title":"Real-world long-term effectiveness of ustekinumab in Crohn\u2019s disease: Results from the ENEIDA registry","volume":"52","author":"Iborra","year":"2020","journal-title":"Aliment. Pharmacol. Ther."}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/13\/3\/73\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:07:12Z","timestamp":1784891232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/13\/3\/73"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["pharmacy13030073"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy13030073","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]}}}